Enzychem files patent application for COVID-19 drug candidate

By The Science Advisory Board staff writers

Enzychem Lifesciences has filed a provisional patent application with the U.S. Patent and Trademark Office to cover treating COVID-19 with its compound EC-18.

EC-18 can resolve inflammation by allowing complete viral clearance while minimizing tissue damage, and it may be able to quickly neutralize SARS-CoV-2 by preventing cytokine storm or acute respiratory distress syndrome, according to the company.

Now the company is seeking appropriate partners to develop and commercialize EC-18 worldwide as a potential treatment for COVID-19.

Copyright © 2020 scienceboard.net

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a Scienceboard.net password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking